Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

R EdelmanCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

Search for other papers by R Edelman in
Current site
Google Scholar
PubMed
Close
,
C O TacketCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

Search for other papers by C O Tacket in
Current site
Google Scholar
PubMed
Close
,
S S WassermanCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

Search for other papers by S S Wasserman in
Current site
Google Scholar
PubMed
Close
,
S A BodisonCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

Search for other papers by S A Bodison in
Current site
Google Scholar
PubMed
Close
,
J G PerryCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

Search for other papers by J G Perry in
Current site
Google Scholar
PubMed
Close
, and
J A MangiaficoCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

Search for other papers by J A Mangiafico in
Current site
Google Scholar
PubMed
Close

We conducted a phase II, randomized, double-blind, placebo-controlled, safety and immunogenicity study of a serially passaged, plaque-purified live chikungunya (CHIK) vaccine in 73 healthy adult volunteers. Fifty-nine volunteers were immunized one time subcutaneously with the CHIK vaccine and 14 were immunized with placebo (tissue culture fluid). Vaccinees were clinically evaluated intensively for one month, and had repeated blood draws for serological assays (50% plaque-reduction neutralization test) for one year. Except for transient arthralgia in five CHIK vaccinees, the number and severity of local and systemic reactions and abnormal laboratory tests after immunization were similar in CHIK vaccinees and placebo recipients. Fifty-seven (98%) of 58 evaluable CHIK vaccinees developed CHIK neutralizing antibody by day 28, and 85% of vaccinees remained seropositive at one year after immunization. No placebo recipients seroconverted. This promising live vaccine was safe, produced well-tolerated side effects, and was highly immunogenic.

Save